ArticleGeroScience2017
CMV immune evasion and manipulation of the immune system with aging.
Article in GeroScience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it.
- B-Cell Immunophenotyping to Predict Vaccination Outcome in the Immunocompromised - A Systematic Review.Frontiers in immunology · 2021Pooled it
- Longitudinal infection trajectories and biological aging acceleration in adults: a prospective cohort study.GeroScience · 2026Article
- Beyond the gut microbe: Rethinking infection, microbiome harmony, and the one-health continuum.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- The impact of cytomegalovirus coinfection on tuberculosis in the mouse model.BMC infectious diseases · 2026Article
- Advances in immunotherapy for cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation.Immunotherapy · 2026Review
- The Dynamics of Human Cytomegalovirus Markers in Tuberculosis Disease Among People With Human Immunodeficiency Virus on Long-term Antiretroviral Therapy: A Nested Case-Control Study.Open forum infectious diseases · 2026Article
- Clinical and immunological analysis of letermovir for preventing cytomegalovirus infection in children after hematopoietic stem cell transplantation.Frontiers in immunology · 2026Article
- Article
- Distinct Immunological Landscapes of HCMV-Specific T Cells in Bone Marrow and Peripheral Blood.Pathogens (Basel, Switzerland) · 2025Article
- Cytomegalovirus-induced oncomodulation drives immune escape in glioblastoma.Scientific reports · 2025Article
- Human herpesvirus reactivation and its potential role in the pathogenesis of post-acute sequelae of SARS-CoV-2 infection.GeroScience · 2025Review
- Discrimination of primary and chronic cytomegalovirus infection based on humoral immune profiles in pregnancy.The Journal of clinical investigation · 2024Article
- Lingering Effects of Early Institutional Rearing and Cytomegalovirus Infection on the Natural Killer Cell Repertoire of Adopted Adolescents.Biomolecules · 2024Article
- Human Cytomegalovirus Oncoprotection across Diverse Populations, Tumor Histologies, and Age Groups: The Relevance for Prospective Vaccinal Therapy.International journal of molecular sciences · 2024Article
- Immune evasion byFrontiers in immunology · 2024Article
- Detection of Human cytomegalovirus UL55 Gene and IE/E Protein Expression in Colorectal Cancer Patients in Egypt.BMC cancer · 2023Article
- Cytomegalovirus infection induces Alzheimer's disease-associated alterations in tau.Journal of neurovirology · 2023Article
- Atypical patterns of human cytomegalovirus infection and spread in U373 glioblastoma cells.Virus research · 2023Article
- Predicting the loss of hepatitis B surface antigen following haematopoietic stem cell transplantation in patients with chronic HBV infection.Bone marrow transplantation · 2023Article
- Association of Cytomegalovirus Serostatus With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Responsiveness in Nursing Home Residents and Healthcare Workers.Open forum infectious diseases · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Human cytomegalovirus (HCMV) encodes numerous proteins and microRNAs that function to evade the immune response and allow the virus to replicate and disseminate in the face of a competent innate and acquired immune system. The establishment of a latent infection by CMV, which if completely quiescent at the level of viral gene expression would represent an ultimate in immune evasion strategies, is not sufficient for lifelong persistence and dissemination of the virus. CMV needs to reactivate and replicate in a lytic cycle of infection in order to disseminate further, which occurs in the face of a fully primed secondary immune response. Without reactivation, latency itself would be redundant for the virus. It is also becoming clear that latency is not a totally quiescent state, but is characterized by limited viral gene expression. Therefore, the virus also needs immune evasion strategies during latency. An effective immune response to CMV is required or viral replication will cause morbidity and ultimately mortality in the host. There is clearly a complex balance between virus immune evasion and host immune recognition over a lifetime. This poses the important question of whether long-term evasion or manipulation of the immune response driven by CMV is detrimental to health. In this meeting report, three groups used the murine model of CMV (MCMV) to examine if the contribution of the virus to immune senescence is set by the (i) initial viral inoculum, (ii) inflation of T cell responses, (iii) or the balance between functionally distinct effector CD4+ T cells. The work of other groups studying the CMV response in humans is discussed. Their work asks whether the ability to make immune responses to new antigens is compromised by (i) age and HCMV carriage, (ii) long-term exposure to HCMV giving rise to an overall immunosuppressive environment and increased levels of latent virus, or (iii) adapted virus mutants (used as potential vaccines) that have the capacity to elicit conventional and unconventional T cell responses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.